Literature DB >> 12955666

The solubility ceiling: a rationale for continuous infusion amphotericin B therapy?

Russell E Lewis, Nathan P Wiederhold.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2003        PMID： 12955666     DOI： 10.1086/377279

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN： 1058-4838            Impact factor:   9.079


× No keyword cloud information.
  11 in total

1.  Slow response of invasive Candida krusei infection to amphotericin B in a clinical time-kill study.

Authors:  L Majoros; I Szegedi; G Kardos; C Erdész; J Kónya; C Kiss
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2006-12       Impact factor: 3.267

Review 2.  Clinical pharmacokinetics of inhaled antimicrobials.

Authors:  Chris Stockmann; Jessica K Roberts; Venkata K Yellepeddi; Catherine M T Sherwin
Journal:  Clin Pharmacokinet       Date:  2015-05       Impact factor: 6.447

3.  Unpredictable In Vitro Killing Activity of Amphotericin B against Four Candida auris Clades.

Authors:  Zoltán Papp; Andrew M Borman; Lajos Forgács; Renátó Kovács; Zoltán Tóth; Chiu Chun-Ju; Gábor Kardos; Béla Juhász; Judit Szilvássy; László Majoros
Journal:  Pathogens       Date:  2021-08-06

Review 4.  Pharmacokinetics and pharmacodynamics of antifungals in children and their clinical implications.

Authors:  Chris Stockmann; Jonathan E Constance; Jessica K Roberts; Jared Olson; Elizabeth H Doby; Krow Ampofo; Justin Stiers; Michael G Spigarelli; Catherine M T Sherwin
Journal:  Clin Pharmacokinet       Date:  2014-05       Impact factor: 6.447

Review 5.  Antifungal therapy for invasive fungal diseases in allogeneic stem cell transplant recipients: an update.

Authors:  Dustin T Wilson; Richard H Drew; John R Perfect
Journal:  Mycopathologia       Date:  2009-03-24       Impact factor: 2.574

6.  continuous versus conventional infusion of amphotericin B deoxycholate: a meta-analysis.

Authors:  Matthew E Falagas; Drosos E Karageorgopoulos; Giannoula S Tansarli
Journal:  PLoS One       Date:  2013-10-21       Impact factor: 3.240

7.  Characteristics of pulmonary mucormycosis and the experiences of surgical resection.

Authors:  Weipeng Shao; Jun Zhang; Shanwu Ma; Hongxiang Feng; Zhenrong Zhang; Chaoyang Liang; Deruo Liu
Journal:  J Thorac Dis       Date:  2020-03       Impact factor: 2.895

8.  Covid-associated pulmonary mucormycosis.

Authors:  Arvind Kumar; Mohan V Pulle; Belal B Asaf; Harsh V Puri
Journal:  Lung India       Date:  2022 Mar-Apr

9.  Combination antifungal therapy involving amphotericin B, rapamycin and 5-fluorocytosine using PEG-phospholipid micelles.

Authors:  Ronak Vakil; Kayla Knilans; David Andes; Glen S Kwon
Journal:  Pharm Res       Date:  2008-04-16       Impact factor: 4.580

10.  Outcomes of early anti-fungal therapy with aggressive surgical resection in pulmonary mucormycosis.

Authors:  Mohan Venkatesh Pulle; Harsh Vardhan Puri; Belal Bin Asaf; Sukhram Bishnoi; Shikha Sharma; Arvind Kumar
Journal:  Lung India       Date:  2021 Jul-Aug
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.